MRNA Stock Approaching 52-Week High

During today's evening trading session, Moderna took the market by storm, rocketing to $154.84 per share despite it now being above its mean target price of $142.2. This 6.5% movement implies there may not be much more room for upwards movement for the stock -- if its analysts are to be believed. They are giving the Biotechnology stock on average rating of buy, with target prices ranging from 62.0 to 310.0 dollars per share.

We can use Moderna's short interest as a proxy for determining general market sentiment regarding the stock. The short interest is the percentage of the share float that represents short positions, meaning that the investor believes the stock will decline in the future. Since MRNA's short interest is 7.4%, the market sentiment is mixed on this stock.

When a stock is sold short, it means an investor has borrowed shares of the stock from their broker, and then sold them at the going market price. The investor hopes for the price to decline, so that they might buy those shares back at a lower price in the future. Once they do, they can return the borrowed shares to their broker, and keep the profit they made on the transaction.

Another way to gauge the sentiment on Moderna is to look at the percentage of institutions that are invested in the stock. In this case, 73.3% of the shares are held by pension, mutual, and hedge funds, which shows that these institutions probably have strong confidence in the stock.

If institutions are invested in a particular stock, it shows in most cases that they have performed quality research and concluded that it is a good investment. In some cases, however, increases in institutional ownership could be a sign of a takeover attempt or proxy fight, which can actually injure share prices. Also, institutions are not infallible, and can certainly make miscalculations -- often with spectacular results.

Overall, there is mixed market sentiment on Moderna because its an analyst consensus of little upside potential, a buy rating, an average amount of shares sold short, and an average number of institutional investors. Warren Buffett famously said that in the short term, markets are voting mechanisms, but in the long term, they are weighing mechanisms. This means that long term investors should be aware of a stock's fundamentals before committing.

Buffett was one of the fist investors to focus on free cash flow as a yardstick for a company's health. Here are MRNA's recent cash flows:

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 -3,118,000 707,000 -3,825,000 -183.5
2022 4,981,000 400,000 4,581,000 -65.65
2021 13,620,000 284,000 13,336,000 580.76
2020 2,027,000 68,000 1,959,000 498.98
2019 -459,000 32,000 -491,000 -12.45
2018 -330,865 105,766 -436,631
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.